Jennison Associates
URGN icon

Jennison Associates’s UroGen Pharma URGN Stock Holding History

Jennison Associates’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-148,575
Closed -$4.68M – 700
2017
Q3 		$4.68M Sell
148,575
-26,835
-15% -$592K ﹤0.01% 506
2017
Q2 		$3.17M Buy
+175,410
New +$3.05M ﹤0.01% 523

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DP
DSAM Partners London, United Kingdom $176M AUM 83.78% 1-Year Est. Return

Jennison Associates's URGN Position: Q4 2017 in Review

Jennison Associates sold out of UroGen Pharma (URGN) in Q4 2017, closing a stake of 148,575 shares — an estimated $4.68M sold.

Jennison Associates first reported a position in URGN in Q2 2017 and held it in 2 quarters. The position peaked at $4.68M in Q3 2017. 41 funds tracked by Wall St. Rank hold URGN as of Q4 2017.

  • Jennison Associates reported no remaining UroGen Pharma position as of Q4 2017 after selling out during the quarter.
  • Jennison Associates sold 148,575 UroGen Pharma shares in Q4 2017, an estimated $4.68M.
  • Jennison Associates first reported a position in UroGen Pharma in Q2 2017 and held it in 2 quarters.
  • Jennison Associates's UroGen Pharma position peaked at $4.68M in Q3 2017.
  • 41 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2017.

Based on Jennison Associates's 13F filing for Q4 2017, filed 25 Jan 2018.